Disclaimer:All content on this platform is sourced from the internet and is provided for informational purposes only. None of the content represents the views of this site, nor does it constitute investment advice. Please exercise caution when investing.

Faster global financial news!

Definium Therapeutics (DFTX) announced positive results from its LSD-based drug in a second Phase 3 study, with patients showing a 5.4-point improvement in anxiety symptoms, exceeding market expectations, causing the stock price to surge.

12/08/2026 13:46 UTC
Share
Complaint Report
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
i
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.